Lund, Sweden, May 30, 2013 - Active Biotech (NASDAQ OMX NORDIC: ACTI) is scheduled to present at the Jefferies 2013 Global Healthcare Conference held June 3-6, 2013 in New York, US. During the presentation, an update regarding Active Biotech's development programs will be provided.
The presentation will include the laquinimod project, a novel oral immunomodulatory drug primarily for the treatment of multiple sclerosis, licensed to Teva Pharmaceutical, the Phase III prostate cancer project tasquinimod in co-development with Ipsen, as well as ANYARA, Active Biotech's novel concept for tumor therapy of primarily renal cell cancer. Also, the project 57-57 (paquinimod) and the pre-clinical ISI project will be presented.
The audio and slide presentation will be webcasted live and can be accessed via the Active Biotech web site. To access the live and replay presentations please go to - www.activebiotech.com.
The presentation will take place on June 4, at 4:00 pm EDT (Eastern Daylight Time) / 22.00 Central European Summer Time.
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, tasquinimod for prostate cancer and ANYARA primarily for the treatment of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. The company also has one additional project in clinical development, the orally administered compound paquinimod (57-57) for systemic sclerosis. Please visit www.activebiotech.com for more information.
Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 10:00 a.m. CEST on May 30, 2013.
